Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myelomaMatthew J. Rees, Shaji Kumar, Arwa Bohra et al.|Blood Cancer Journal|2024Cited by 20
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Shaji Kumar, Dragan Jevremović et al.|Blood Cancer Journal|2025Cited by 8